Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIT-013 dose-ranging placebo-controlled Phase IIa trial in moderately active rheumatoid arthritis
2024-517356-35-00Phase 2Authorised
- Sponsor
- Citryll
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of CIT013 in rheumatoid arthritis (RA) (4 arms), sponsored by Citryll. Primary endpoint: Mean change in DAS28-CRP at day 43 for pooled 50 mg and 100 mg CIT-013 versus placebo. Planned start Jul 2025; status: authorised.
02
Drugs
CIT013
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-517356-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517356-35-00.